$PACB

PacBio (PACB) and Verily Health have formed a multi-year collaboration to integrate PacBio's HiFi sequencing with Verily's data and AI platform. The partnership aims to combine long-read genomic data with clinical data for biomedical discovery and AI model training. Verily Pre Workbench will connect PacBio sequencing workflows for researchers. The companies plan to expand the integration across research organizations and biopharma.

Roche, Novartis, Pfizer, and Eli Lilly received FDA approvals for their drugs. Lupin and Lipocine also gained regulatory nods. Caribou Biosciences plans to cut workforce and discontinue programs. Several biopharma companies announced deals and partnerships. Stock prices for mentioned companies varied.

Gibson James R II (See Remarks) sold 661,815 shares of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) at $3.11 ($2.06M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Pacific Biosciences (PACB), Fortrea (FTRE), Alamar (ALMR), 10x Genomics (TXG), and Azenta (AZTA) reached 52-week highs on October 6, 2026. PACB announced a collaboration with TychoBio, FTRE reported Q2 revenue of $678M, ALMR saw Q2 revenue surge to $29.43M, TXG launched the Atera platform, and AZTA reported 12% Q3 revenue growth.

Pacific Biosciences of California Inc. (PACB) fell 5.23% after UBS initiated coverage with a Neutral rating and a $1.35 price target, below its $2.70 closing price. The company reported $39.0M in quarterly revenue, a net loss of $44.7M, and has $236.9M in cash. UBS views PACB as a long-term growth play in the life sciences tools sector.

PacBio shares fell 8% after TychoBio announced it will use PacBio's long-read sequencing for over 10,000 samples. The deal lacks a stated value, and PacBio's revenue declined from $201M in 2023 to $160M in 2025, with consistent cash burn and share dilution. Investors await evidence of revenue growth from such partnerships.

PacBio (PACB) and TychoBio have partnered to generate RNA data for AI-driven RNA therapy design. TychoBio will use PacBio's HiFi sequencing to analyze 10,000+ samples, aiming to accelerate rare disease treatments. The collaboration focuses on improving therapeutic efficacy and safety through advanced sequencing and AI modeling.

Pacific Biosciences of California (PACB) shares rose 15% to $2.88 after EpiSign and Geneyx announced a partnership using PacBio's HiFi sequencing for rare disease analysis. The stock is up 56.5% year-to-date, reaching a 52-week high. PacBio's shares are volatile, with 87 moves over 5% in the past year.

Pacific Biosciences (PACB) stock rose 29.7% after EpiSign launched EpiSign METRIC 5-base, a software for DNA methylation data analysis on PacBio's HiFi sequencing platform. The tool also supports Illumina and Oxford Nanopore platforms. PacBio's shares have seen high volatility, with an 86% move over the past year. The stock is up 30.4% YTD but still 9.9% below its 52-week high.

PacBio (PACB) rose 5.8% after a $27.1M contract with the U.S. Department of Veterans Affairs. Nvidia (NVDA) gained 2.7% following a $150B share buyback authorization. Palo Alto Networks (PANW) increased 5.1% after BTIG raised its price target to $425. Teleflex (TFX) climbed 4.5% following a BofA Securities upgrade.